Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H39NO2
CAS Number:
Molecular Weight:
313.52
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 5 mg (860478P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
CCCCCCCCCCCCC/C=C(C)\[C@@H](O)[C@@H](N)CO
InChI
1S/C19H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(2)19(22)18(20)16-21/h15,18-19,21-22H,3-14,16,20H2,1-2H3/b17-15-/t18-,19+/m0/s1
InChI key
LMJPKTKGCMCPGM-PIIWLPLESA-N
General description
cis-4-methylsphingosine (cis-4M-Sph) is a methyl-branched sphingosine analog.
Biochem/physiol Actions
cis-4-methylsphingosine (cis-4M-Sph) modulates sphingosine 1 phosphate (S1P) receptor through its metabolite cis-4-methylsphingosine-1-phosphate (cis-4M-S1P). This leads to S1P receptor internalization and desensitization. cis-4M-Sph shows an inhibitory effect on serine palmitoyltransferase activity.
Packaging
5 mL Amber Glass Screw Cap Vial (860478P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
wgk
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
G van Echten-Deckert et al.
The Journal of biological chemistry, 272(25), 15825-15833 (1997-06-20)
The effect of six different structurally modified sphingosine analogues on biosynthesis of sphingolipids was studied in primary cultured murine cerebellar neurons. Treatment of cells with cis-4-methylsphingosine at micromolar levels resulted in a markedly decreased sphingolipid biosynthesis, whereas the other compounds
Michael Ter Braak et al.
Biochemical pharmacology, 81(5), 617-625 (2010-12-18)
Sphingosine-1-phosphate (S1P) acts as high affinity agonist at specific G-protein-coupled receptors, S1P(1-5), that play important roles e.g. in the cardiovascular and immune systems. A S1P receptor modulating drug, FTY720 (fingolimod), has been effective in phase III clinical trials for multiple
Wenzheng Xia et al.
Molecular medicine reports, 16(5), 7039-7047 (2017-09-14)
Mesenchymal stem cell (MSC)‑based therapies have demonstrated efficacy in animal models of cardiovascular diseases. However, MSCs decrease in quantity and quality with age, which reduces their capacity for damage repair. Long noncoding (lnc) RNAs regulate gene transcription and the fate